Predict your next investment

kestrelmanagement.com

See what CB Insights has to offer

Investments

48

Portfolio Exits

15

Funds

5

Partners & Customers

1

About Kestrel Management

Kestrel Management Headquarter Location

5750 Old Orchard Rd

Skokie, Illinois, 60077-4402,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kestrel Management News

Cognoptix Forms a New Board of Directors

Jan 19, 2021

Cognoptix Forms a New Board of Directors Cognoptix Forms a New Board of Directors The board is now comprised of a mix of healthcare investors and a leading expert on biomarker discovery. PR Newswire01.19.21 Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix' new president and CEO. In addition to Dr. Wilke, the five-member board includes Dr. Lee E. Goldstein, Cognoptix co-founder and co-chair of the company's Scientific Advisory Board (SAB); R. Gregg Stone and John Conley, both are members of the Launchpad Venture Group which led the Cognoptix Series R fundraising and is a nationally recognized leader among angel networks; and H. Lawrence Remmel, partner and chair of the Banking and Finance Group at Pryor Cashman. Goldstein is a leading expert on biomarker discovery in AD and CTE. Dr. Goldstein directs the Molecular Aging & Development Laboratory and co-leads the Biomarker Core of the Boston University Alzheimer's Disease Research Center and Boston University Center for Translational Neuroimaging. He started his career at Brigham & Women's Hospital, Harvard Medical School. Late last year, Cognoptix announced Dr. Goldstein's new roles in the company and an overview of his groundbreaking research that underpins the Cognoptix SAPPHIRE II system. Stone and Conley are both seasoned healthcare investors with lengthy track records of successfully guiding and directly leading healthcare companies. "In Cognoptix, I saw a technology with the potential to transform detection and care in a disease that is devastating to millions of patients and their families. SAPPHIRE II is a breakthrough technology because it will allow for safe, non-invasive early detection of this disease at a stage when interventions will make the most difference," said Stone. "Under Dr. Wilke's leadership, Cognoptix is soon to begin its pivotal trial and is pursuing the partnerships needed for successful global commercialization," Conley added. Remmel brings, in addition to his tremendous legal and financial expertise, extensive biotech expertise, i.e., with CytoDel and Aufbau Holdings, two biotech companies developing therapeutics in the neuro and ophthalmology areas, respectively. "Cognoptix's Board of Directors will provide crucial leadership to guide the transformation of the company from its previous R&D focus, to achieving FDA approval and commercialization of its SAPPHIRE II system," said Dr. Wilke. Cognoptix has successfully completed two proof-of-concept clinical studies, both of which showed that the Sapphire II system not only can accurately detect Alzheimer's β-amyloid (Ab) in the lens of patients with mild cognitive impairment (MCI) or early-stage AD but may also be more sensitive than amyloid PET brain scans, the current gold standard for Ab detection. Cognoptix is launching the final stage of its development program in preparation for a pivotal clinical study in 2021. The goal of this study is to replicate the strong results obtained during pre-pivotal testing. Dr. Susanne Wilke, Ph.D., MBA is the president and CEO of Cognoptix. Dr. Wilke is an experienced executive with over 30 years of experience in drug development, venture capital financing, and operations having held senior positions in pharmaceuticals, biotechnology, venture capital, and healthcare consulting. Prior to joining Cognoptix, Dr. Wilke served as the CEO and a director of Neurotrope Biosciences, a clinical-stage biotech company focused on neurodegenerative diseases, including Alzheimer's. Previously, she was founder and managing partner of CrossBridge International, a healthcare advisory firm focused on strategy and capital formation. Dr. Wilke's industry experience includes positions at Forest Labs, Roche Pharmaceuticals and Amgen. She was also a venture investor at SV Life Sciences and NGN Capital. Lee E. Goldstein, M.D., Ph.D., is the co-founder of Cognoptix. Dr. Goldstein's lab, originally at Brigham & Women's Hospital, Harvard Medical School, and now at Boston University School of Medicine and Alzheimer's Disease Research Center, made the seminal discovery that Ab accumulates in the lens of patients with Alzheimer's disease. This finding is the first evidence of AD-linked Ab pathology outside the brain. Dr. Goldstein confirmed in detailed studies using mass spectroscopy peptide mapping and other techniques that amyloid deposit in the lens of the eye mirror beta-amyloid deposits in the brain. Dr. Goldstein and his team were first to predict, and then identify, identical AD-linked Ab lens pathology in people with Down syndrome, a common chromosomal disease that also results in early-onset Aβ pathology in the brain. He directs the Molecular Aging & Development Laboratory and co-leads the Biomarker Core of the Boston University Alzheimer's Disease Research Center and Boston University Center for Translational Neuroimaging. Dr. Goldstein's research provided the foundational science that underpins Cognoptix' mission. He has received awards from the Alzheimer's Association, American Federation for Aging Research, Optical Society of America, National Institutes of Health, Harvard Medical School, and Oxford University. R. Gregg Stone is the founder of Kestrel Management. For almost 40 years, he has been an active business investor as an angel investor of seed-stage companies' development and board member to selecting public market managers. He is an active member of Launchpad Venture Group, the largest angel group in the Northeast. Stone currently serves as a director to Cambridge Trust Company and another private company. Until its sale to eRT in 2015, he served as the chairman of PHT Corp, a pharmaceutical service company based in Charlestown, Mass. Prior and current investments include NovaCare, Health Dialog, CardioFocus and Iora Healthcare. Before founding Kestrel in 1996, he worked as an investment adviser and practiced law in Boston. John Conley co-founded Gilliam Capital LLC, a life science investment firm, and is a member and director of Launchpad Venture Group, Cognoptix' founding investor and syndicate lead. He is a board member for three healthcare startups and works with a variety of social enterprises. John was the chief operating officer of Entrepreneurship for All, a nonprofit that is accelerating economic and social impact through fostering entrepreneurship in mid-sized cities. Previously, he was co-founder and chief financial officer of Alnylam Pharmaceuticals through its successful initial public offering. He also held various business development, marketing, sales and finance positions at Transkaryotic Therapies and Biogen and was a strategic consultant at Bain & Company. H. Lawrence Remmel is a partner at Pryor Cashman LLP, a New York law firm, where he serves as chair of the Banking and Finance practice group. His practice includes corporate and banking financing issues relating to the Investment Company Act of 1940 and intellectual property and licensing issues, particularly in the biotechnology and bio-cosmeceutical areas. Larry is a board member of Atossa Therapeutics Inc., a company focused on the development and marketing of pharmaceuticals for the treatment of breast cancer and similar conditions; CytoDel Inc., an early-stage biopharmaceutical company developing products for biodefense, neuronal drug delivery, and musculoskeletal and aesthetic medicine; and Aufbau Holdings Ltd., an Irish company developing diagnostics and therapeutics in ophthalmology, oncology and other areas.

Kestrel Management Investments

48 Investments

Kestrel Management has made 48 investments. Their latest investment was in CardioFocus as part of their Series C on February 2, 2011.

CBI Logo

Kestrel Management Investments Activity

investments chart

Kestrel Management Portfolio Exits

15 Portfolio Exits

Kestrel Management has 15 portfolio exits. Their latest portfolio exit was PHT Corporation on February 27, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/27/2015

Acquired

1

3/11/2010

Acquired

$99M

1

6/9/2008

Acquired

$99M

5/8/2008

Acquired

Subscribe to see more

Subscribe to see more

10

2/24/2006

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

2/27/2015

3/11/2010

6/9/2008

5/8/2008

2/24/2006

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

10

0

Kestrel Management Fund History

5 Fund Histories

Kestrel Management has 5 funds, including Massachusetts Ventures Equity Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/14/1997

Massachusetts Ventures Equity Fund

Multi-Stage Venture Capital

Closed

$14M

1

3/1/1997

Kestrel Venture Partners, L.P.

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1993

Corning Partners IV, L.P.

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1992

Corning Partners III, L.P.

Subscribe to see more

Subscribe to see more

$99M

10

12/31/1987

Corning Partners II, L.P.

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/14/1997

3/1/1997

12/31/1993

12/31/1992

12/31/1987

Fund

Massachusetts Ventures Equity Fund

Kestrel Venture Partners, L.P.

Corning Partners IV, L.P.

Corning Partners III, L.P.

Corning Partners II, L.P.

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$14M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Kestrel Management Partners & Customers

1 Partners and customers

Kestrel Management has 1 strategic partners and customers. Kestrel Management recently partnered with Ultra Consultants on January 1, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

1/24/2019

Partner

Ultra Consultants

United States

Kestrel Forms Alliance with Ultra Consultants to Enhance Food Safety Offerings

MADISON , WISCONSIN -LRB- January 22 , 2019 -RRB- -- Kestrel Management on Tuesday announced a partnership with Ultra -LRB- Ultra -RRB- to provide food safety compliance and remediation advisory services to North American food and beverage processors .

1

Date

1/24/2019

Type

Partner

Business Partner

Ultra Consultants

Country

United States

News Snippet

Kestrel Forms Alliance with Ultra Consultants to Enhance Food Safety Offerings

MADISON , WISCONSIN -LRB- January 22 , 2019 -RRB- -- Kestrel Management on Tuesday announced a partnership with Ultra -LRB- Ultra -RRB- to provide food safety compliance and remediation advisory services to North American food and beverage processors .

Sources

1

Kestrel Management Team

1 Team Member

Kestrel Management has 1 team member, including former General Partner, Nuri A.E.Z. Wissa.

Name

Work History

Title

Status

Nuri A.E.Z. Wissa

General Partner

Former

Name

Nuri A.E.Z. Wissa

Work History

Title

General Partner

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.